Rat Carboxymethyl lysine ELISA Kit

BACKGROUND: Braised chicken is one of the well-known traditional processed meat products in China. However, reports are scarce with respect to the formation of N-e-carboxymethyllysine (CML) and N-e-carboxyethyllysine (CEL) during chicken braising. Furthermore, braising for a long time and using high-temperature process will result in water loss. However, the relationship between water loss and advanced glycation end products (AGEs) kinetics is limited. The present study aimed to investigate the relationship between water loss and kinetics of free and protein-bound CML and CEL in braised chicken under different braising conditions (60-100 degrees C for 5-60 min). RESULTS: Levels of free and protein-bound CML and CEL were found to increase with heating time and temperature. The correlation coefficient (r(2)) was largest at zero-order reaction (free CML: r(2) = 0.908-0.954, protein-bound CML: r(2) = 0.901-0.958, free CEL: r(2) = 0.952-0.973, protein-bound CEL: r(2) = 0.959-0.965). The activation energy was 44.158 +/- 3.638 kJ mol(-1) for free CML, 40.041 +/- 3.438 kJ mol(-1) for protein-bound CML, 40.971 +/- 0.334 kJ mol(-1) for free CEL and 40.247 +/- 0.553 kJ mol(-1) for protein-bound CEL. Furthermore, with the increase of braising time and temperature, the drip loss and cooking loss also became aggravated. A significant positive correlation between water loss and AGEs levels during braising was observed by Pearson's correlation analysis (P < 0.05). CONCLUSION: We conclude that the levels of free and protein-bound CML and CEL during braising were different, although they all met zero-order reaction kinetics. Water loss was probably one of the main reasons for the formation of AGEs during chicken braising. (c) 2020 Society of Chemical Industry

We assessed the quality of life and symptom burden in patients with chronic-phase chronic myeloid leukemia (CML) receiving first- or second-generation tyrosine kinase inhibitors, to demonstrate whether there are differences between tyrosine kinase inhibitor generations. A total of 121 patients with CML with good performance and low comorbidity scores were enrolled in the study. Similar results were observed between the groups in the quality of life and symptom burden scores, which were examined using CML-specific (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chronic Myeloid Leukemia module, MD Anderson Symptom Inventory for Chronic Myeloid Leukemia) questionnaires. Background: With the advent of tyrosine kinase inhibitors (TKIs), patients with chronic myeloid leukemia (CML) have a life expectancy similar to those of age- and gender-matched healthy populations. Nevertheless, patients receiving TKIs report chronic adverse events such as fatigue, edema, and muscle cramps, which lead to a decrease in their quality of life (QoL). Therefore, the aim of this study was to assess the QoL and symptom burden in patients receiving original imatinib, generic imatinib, dasatinib, and nilotinib. Patients and Methods: A total of 121 patients with CML who received TKIs for at least 3 months were enrolled in the study. The QoL was assessed with the Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and Quality of Life Questionnaire-Chronic Myeloid Leukemia (QLQ-CML24) modules. The symptom burden was assessed with MD Anderson Symptom Inventory for Chronic Myeloid Leukemia (MDASI-CML) and EORTC QLQ-CML24. Results: The median age of the study population was 53 years (range, 28-90 years), and 83 (81.4%) patients had a low-to-medium Sokal risk score. The Eastern Cooperative Oncology Group performance status of most patients were good (< 2; 96%), and comorbidity scores were low (HCT-CI < 3; 90.8%). There was no significant difference between the general health status of patients in terms of EORTC QLQ-C30 and QLQ-CML24. According to the results of the MDASI-CML and QLQ-CML24 modules, the most common symptom was fatigue (58.7%) in all groups, and there were no significant differences between the groups in terms of the effects on the daily life activities of the patients. Conclusion: Patients with CML receiving first- and second-generation TKIs were seen to have a similar QoL and symptom burden. (C) 2020 Elsevier Inc. All rights reserved.